WAVE Life Sciences is a clinical-stage biotechnology company focused on the discovery, development and commercialization of nucleic acid therapies using its proprietary stereopure oligonucleotide platform. Founded in 2017 as a spinout from Harvard University and Massachusetts General Hospital, WAVE has pioneered a chemistry-based approach that allows precise control over the three-dimensional structure of therapeutic RNA or DNA molecules. This stereopure technology is designed to enhance potency, durability and safety compared to traditional oligonucleotide therapies, positioning WAVE as an innovator in the rapidly evolving field of genetic medicine.
The company’s pipeline encompasses programs in rare genetic diseases and oncology. Key candidates include treatments for Huntington’s disease, myotonic dystrophy type 1 and other neuromuscular disorders, as well as a collaboration with Pfizer to develop novel RNA-targeting therapeutics for oncology indications. WAVE’s lead programs have advanced into mid- and late-stage clinical trials, reflecting the company’s progress in translating preclinical success into potential therapies for patients with high unmet medical needs.
Headquartered in Cambridge, Massachusetts, WAVE Life Sciences operates additional research and development sites in Cambridge, UK, and Singapore. The company’s global footprint enables collaboration with academic institutions, regulatory agencies and commercial partners around the world. WAVE is committed to expanding its manufacturing capabilities and regulatory expertise to support future product approvals and ensure broad patient access across North America, Europe and Asia-Pacific regions.
Led by President and Chief Executive Officer Paul A. Bolno, M.D., WAVE’s management team brings extensive experience in drug development, regulatory affairs and commercialization. The leadership team includes seasoned industry veterans formerly associated with major pharmaceutical and biotechnology companies, underscoring WAVE’s strategic focus on advancing complex nucleic acid therapies from the laboratory to the clinic. With a robust intellectual property portfolio and a clear clinical development strategy, WAVE Life Sciences is positioned to be a leader in stereopure oligonucleotide-based medicines.
AI Generated. May Contain Errors.
